Open-label support for duloxetine for the treatment of panic disorder

CNS Neuroscience and Therapeutics

Volumn 15, Issue 1, 2009, Pages 19-23

  Simon, Naomi M ^a   Kaufman, Rebecca E ^a   Hoge, Elizabeth A ^a   Worthington, John J ^a   Herlands, Nannette N ^a   Owens, Maryann E ^a   Pollack, Mark H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressant; Anxiety; Duloxetine; Panic; Pharmacotherapy; Treatment

Indexed keywords

DULOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; AGORAPHOBIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; NERVOUSNESS; PANIC; PANIC DISORDER SEVERITY SCALE; QUALITY OF LIFE; RATING SCALE; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TRANQUILIZING ACTIVITY; URINARY HESITANCY; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 60349103747     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00076.x     Document Type: Article

References (15)

1. Kessler RC, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006 63 (4 415 424.
2. Pollack MH. The pharmacotherapy of panic disorder. J Clin Psychiatry 2005 66(Suppl 4 23 27.
3. Pollack MH, et al. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry 1994 55 (5 200 205.
4. Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet 2006 368 (9540 1023 1032.
5. Katon WJ. Clinical practice. Panic disorder. N Engl J Med 2006 354 (22 2360 237.
6. Bymaster FP, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001 25 (6 871 80.
7. Trivedi MH, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol 2008 23 (3 161 169.
8. Pollack MH, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007 24 (1 1 14.
9. Pollack M, et al. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007 194 (2 233 242.
10. Shear MK, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry 1997 154 (11 1571 1575.
11. Guy W. Assessment manual for psychopharmacology. US Government Printing Office, 1976.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 134 : 382 389.
13. Endicott J, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 1993 29 (2 321 326.
14. Leon AC, et al. The Range of Impaired Functioning Tool (LIFE-RIFT): A brief measure of functional impairment. Psychol Med 1999 29 (4 869 878.
15. Perna G, et al. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005 30 (12 2230 2235.